Authors: Dowell, JE Garrett, AM Shyr, Y Johnson, DH Hande, KR

Citation: Je. Dowell et al., A randomized phase II trial in patients with carcinoma of an unknown primary site, CANCER, 91(3), 2001, pp. 592-597

Authors: Dang, TP Gazdar, AF Virmani, AK Sepetavec, T Hande, KR Minna, JD Roberts, JR Carbone, DP

Citation: Tp. Dang et al., Chromosome 19 translocation, overexpression of Notch3, and human lung cancer, J NAT CANC, 92(16), 2000, pp. 1355-1357

Authors: Choy, H Devore, RF Hande, KR Porter, LL Rosenblatt, P Yunus, F Schlabach, L Smith, C Shyr, Y Johnson, DH

Citation: H. Choy et al., A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (A Vanderbilt cancer center affiliate network study), INT J RAD O, 47(4), 2000, pp. 931-937

Authors: Rothenberg, ML Nelson, AR Hande, KR

Citation: Ml. Rothenberg et al., New drugs on the horizon: Matrix metalloproteinase inhibitors (reprinted from The Oncologist, vol 3, pg 271-274, 1998), STEM CELLS, 17(4), 1999, pp. 237-240

Authors: Grunberg, SM Crowley, J Hande, KR Giroux, D Munshi, N Lan, DHM Schroder, LE Zangmeister, MH Balcerzak, SP Hynes, HE Gandara, DR

Citation: Sm. Grunberg et al., Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study, CANC CHEMOT, 44(6), 1999, pp. 461-468